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Warfarin, a widely used anticoagulant, is a vitamin K antagonist impairing the activity of vita-
min K-dependent Bone Gla Protein (BGP or Osteocalcin) and Matrix Gla Protein (MGP).
Because dabigatran, a new anticoagulant, has no effect on vitamin K metabolism, the aim
of this study was to compare the impact of warfarin and dabigatran administration on bone
structure and vascular calcification.
Methods
Rats with normal renal function received for 6 weeks warfarin, dabigatran or placebo. Bone
was evaluated immuno-histochemically and hystomorphometrically after double labelling
with declomycin and calcein. Aorta and iliac arteries were examined histologically.
Results
Histomorphometric analysis of femur and vertebrae showed significantly decreased bone
volume and increased trabecular separation in rats treated with warfarin. Vertebra analysis
showed that the trabecular number was higher in dabigatran treated rats. Osteoblast activity
and resorption parameters were similar among groups, except for maximum erosion depth,
which was higher in warfarin treated rats, suggesting a higher osteoclastic activity. There-
fore, warfarin treatment was also associated with higher bone formation rate/bone surface
and activation frequency. Warfarin treatment may cause an increased bone turnover char-
acterized by increased remodelling cycles, with stronger osteoclast activity compared to the
other groups. There were no differences among experimental groups in calcium deposition
either in aortic or iliac arteries.
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Conclusions
These findings suggest for the first time that dabigatran has a better bone safety profile than
warfarin, as warfarin treatment affects bone by reducing trabecular size and structure,
increasing turnover and reducing mineralization. These differences could potentially result
in a lower incidence of fractures in dabigatran treated patients.
Introduction
Warfarin is widely used to prevent venous thrombosis after orthopaedic surgery and strokes in
non-valvular atrial fibrillation. Warfarin inhibits two important reactions of the vitamin K
cycle at the quinone reductase and epoxide reductase levels, causing a functional shortage of
vitamin K [1], a cofactor for γ-glutamyl carboxylase, the enzyme that activates several vitamin
K-dependent proteins (VKDP) through γ-carboxylation, including Matrix Gla Protein (MGP),
an inhibitor of vascular calcification [2, 3], as well as osteocalcin (BGP) and other osteoblast
specific proteins, involved in proper bone mineralization during bone formation [4]. However,
specific ablation of γ-glutamyl carboxylase in osteoblast has demonstrated that γ-carboxylation
is not a pre-requisite for the bone protective effects of vitamin K [4]. Indeed, vitamin K benefits
on bone health also include a positive calcium balance [5] and synergy with vitamin D bone
forming actions [5–7]. Therefore, warfarin induced vitamin K deficiency increases the risk of
developing osteoporosis and bone fragility [8].
Dabigatran is a direct inhibitor of thrombin (serine protease), blocking the conversion of
fibrinogen into fibrin and thereby preventing thrombosis [9]. Unlike warfarin, dabigatran-
driven thrombin inhibition does not interfere with the vitamin K cycle, thus preventing the
risk of vascular calcifications, abnormal skeletal integrity and bone fractures caused by vitamin
K deficiency.
The aim of this study was to compare the impact of warfarin and dabigatran on bone struc-
ture and on arterial calcifications in rats with normal renal function.
Materials and Methods
Animal Protocols
Experimental procedures were carried out following the guidelines for animal experiments
established at the IRB Lleida and specifically approved by the Animal Study Committee at
Lleida Institute, in agreement with the EU Directive 2010/63/EU for animal experiments.
Thirty-four female Sprague-Dawley (SD) rats, 10 weeks old, were randomly divided in three
groups as follows: 1) Normal Controls (Untreated): Rats (n = 10) were fed a control diet con-
taining vitamin K3, at the concentration of 8 mg/kg. Assuming the average intake of chow for a
rat is 15 to 30 g/day, vitamin K3 intake was 120 to 240 μg/day. The diet also contained 1000
IU/kg of vitamin D3, 1.05% calcium, 0.2% magnesium, and 0.8% phosphorus. 2) Dabigatran
Treatment: Rats (n = 10) were fed the same control diet supplemented with dabigatran etexilate
at a concentration of 1.0 mg/g of chow. 3)Warfarin Treatment: Rats (n = 14) were fed the con-
trol diet and received warfarin in the drinking water to reach a concentration sufficient to
obtain an International Normalized Ratio (INR) between 2 and 3. A number equal to 14 ani-
mals was chosen for this group considering the possibility of death due to a high INR.
Specifically, upon arrival to the conventional animal facility, (12:12 hours dark:light cycle),
rats, 2 to 3 in each cage, were subjected to a 4-day period of adaptation to the new control
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chow diet in order to obtain the average daily water intake to estimate the final concentration
of warfarin in the drinking water required to achieve the desired INR starting from the
reported warfarin supplementation of 0.6 mg/kg rat. Rats were treated as indicated for 6 weeks.
INR tests in the warfarin-treated group were conducted in average every 3 days, in order to
ensure proper adjustment of the oral dose of warfarin to avoid INR higher than 3. The warfarin
dose was progressively reduced to 0.2 mg/kg, with an average administration of 0.255 ± 0.001
mg/kg. At the end of the study, rats were moved to the surgery room and anesthetized with the
recommended dose of ketamine 10%: xylazine 2% cocktail intraperitoneally administered
(ketamine 0.09g/kg of rat weight, xylazine 0.01g/kg of rat weight) to collect blood from the
abdominal aorta. Then, euthanasia was performed by exsanguination under deep anesthesia.
Control rats and dabigatran treated rats underwent Hemoclot tests in duplicate, to assess the
anticoagulation activity of dabigatran and to quantify concentrations of dabigatran in plasma,
as previously described [10]. Serum and plasma were kept at -20°C for further analysis.
Vascular Calcification Studies
At necropsy, samples of aorta and iliac arteries were preserved for histological examination.
Specifically, Von Kossa and Alizarin red staining were used to evaluate the degree of calcifica-
tion with treatment.
Bone Studies
Bone labelling was performed using declomycin and calcein, injected i.p. at a concentration of
15 mg/kg body weight, at 10 and 3 days prior to sacrifice, respectively.
Femur, tibia and vertebrae were collected and stored in ethanol for immuno-histochemical
and morphometric analysis of bone remodelling.
Bone Histomorphometry
Rat femurs and vertebrae were embedded undecalcified in a methyl-methacrylate resin (Merck
800590, Germany). Bone sections were cut using a microtome (Leica RM2265, Leica Microsys-
tems, Wetzlar, Germany) equipped with a carbide-tungsten blade, stained with Goldner’s
stain, and mounted on microscope slides for histomorphometric measurements. The sections
were obtained from three different levels of the methyl-methacrylate block, each separated by a
thickness of 250 μm. Histomorphometric results were calculated as the mean of the values
obtained from the three different levels as an approximation to a 3-D evaluation. This also
avoids replicating the sampling of any single bone remodelling unit. For femur analysis, we
analyzed the trabecular and cortical bone of the secondary spongiosa area between 2 and 4 mm
distal to the growth plate-metaphyseal junction in the upper part of the diaphysis (Fig 1A), as
in [11]. Concerning the vertebrae, we selected lumbar vertebrae and considered the middle
area in frontal sections to evaluate trabecular and cortical bone parameters (Fig 1B).
Measurements were performed by means of an image analysis system consisting of an epi-
fluorescent microscope (Leica DM 2005, Leica Microsystems, Wetzlar, Germany) connected to
a digital camera (Leica DFC 420C, Leica Microsystems, Wetzlar, Germany) and a computer
equipped with a specific software for histomorphometric analyses (Bone 3.5, Explora Nova, La
Rochelle, France). Histomorphometric parameters were reported in accordance with the
ASBMR Committee nomenclature [12].
Osteoid Surface (OS/BS, %), Osteoid Thickness (O.Th, μm), Osteoblast Surface (ObS/BS,
%) were measured as static parameters of bone formation. Maximum Erosion Depth (MAX-
EDe, μm), Erosion Surface (ES/BS, %) and the number of osteoclasts (N.Oc/T.A /mm2) evalu-
ated bone resorption. Bone Formation Rate (BFR/BS) and Activation Frequency (AcF)
Dabigatran vs. Warfarin Effects on Bone
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evaluated dynamic parameters of bone formation, reflecting bone turnover. Bone Formation
Rate (BFR/BS) was calculated as Mineralizing Surfaces (MS/BS) X Mineral Apposition Rate
(MAR), and expressed in μm3/μm2/day [12].
Mineral apposition rate (MAR) was calculated as the distance between at least 3 midpoints
of two consecutive labels, divided by the time between the two tetracycline administrations.
MS/BS was calculated as the double-labeled surface (dLS/BS) plus one half of the single-labeled
surface (sLS/BS) expressed as a function of total bone surface.
Thickness results were adjusted for the obliquity of sections by multiplying by π/4. To assess
trabecular microarchitecture, trabecular number (Tb.N), trabecular separation (Tb.Sp, μm),
and trabecular thickness (Tb.Th, μm) were measured [13]. After skeletonization, the trabecular
network was evaluated by measuring the connections between nodes (points at which three or
more trabeculae join), connection branches (struts), terminal or free-ends branches (termini)
and by calculating number of nodes (N.Nd/TV), and nodes/termini ratio (Nd/Tm), as previ-
ously described [14]. Indirect parameters of microarchitecture were also assessed including:
Marrow Star Volume (MSV, N/mm3), which is the mean volume of all the parts of an object
Fig 1. Regions of Interest (ROI) for histomorphometric analyses for femur (1A) and vertebra (1B). For femur analysis, we analyzed the trabecular and
cortical bone (in green) of the secondary spongiosa area between 2 and 4 mm distal to the growth plate-metaphyseal junction in the upper part of the
diaphysis. Concerning the vertebrae, we selected lumbar vertebrae and considered the middle area in frontal sections to evaluate trabecular and cortical
bone parameters.
doi:10.1371/journal.pone.0133847.g001
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that can be unobscured in all the directions from a point inside the object [15]; Fractal Dimen-
sion (D), which describes how an object fills a space according to its structure and which also
evaluates bone structural anisotropy [16].
After thresholding the section to distinguish bone from marrow, the endosteal surface of the
cortex was identified subjectively to exclude trabecular bone and include only bone with a typi-
cal cortical osteonal structure. Cortical porosity was calculated as a percentage of the total corti-
cal area.
Statistical Analysis
Results are expressed as mean ± SD or mean ± SEM. We performed Kolmogorov-Smirnov test
and Levine’s test to verify the normal distribution of the results and the homogeneity of the
variance, respectively. Based on the results of these tests, we used parametric test to analyze dif-
ferences among groups by one-way analysis of variance (ANOVA). A p<0.05 was considered
statistically significant. Differences among pairs of groups were tested with Bonferroni as a
post-hoc test. Statistical analyses were performed by using SPSS for Windows version 21.0
(SPSS Inc., Chicago, IL, USA).
Results
Efficacy of Anticoagulant Treatment
Significant increases of INR and prothrombin time in the warfarin group vs. either dabigatran
or controls were observed (Table 1).
The starting warfarin dose of 0.6 mg/kg was excessive, resulting in elevated INR values and
three deaths. Due to the short exposure to warfarin (4 days), these three animals were excluded
from further analysis. Individualized dose reductions (average = 0.255) allowed obtaining the
desired target INR between 2 and 3, with an overall mean INR of 2.8 ± 0.29. Warfarin treated
rats had a mortality rate of 43% (in total, 6/14 rats died) with evidence of intra-hepatic bleeding
at necropsy. No deaths occurred either in the dabigatran or the control group.
Results of the hemoclot tests at the end of treatment (Table 1) demonstrated effective
anticoagulation achieved in the dabigatran treated rats. Results of the hemoclot (dTT)-assay
indicated a dabigatran plasma concentration of 317.3±30.1nmol/l (equivalent to 149.6±14.2
ng/ml).
Table 1. Anticoagulation parameters (S1 Dataset).
Treatment Prothrombin Time (sec) INR Mean INR Hemoclot test (sec)
Timing End of study End of study Throughout study End of study
Control (n = 10) 9.6 ± 0.1 0.83 ± 0.01 n.a. 31.4 ± 0.4
Warfarin (n = 7) 43.0 ± 8.3 * 4.31 ± 6.27 * 2.8 ± 0.29 n.a.
Dabigatran(n = 10) 11.7 ± 0.4 1.05 ± 0.03 n.a. 48.9±2.0 #
Data are expressed as mean ± SEM
n.a. = not available.
* indicates p<0.001 vs. dabigatran or control
# indicates p<0.001 vs. controls
doi:10.1371/journal.pone.0133847.t001
Dabigatran vs. Warfarin Effects on Bone
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Vascular Calcifications
Under our experimental conditions, there was no evidence of arterial calcium deposition either
in the aorta or in the iliac arteries among the three groups of rats.
Bone Histomorphometry
Ten rats treated with dabigatran and ten control rats were available for histomorphometric
analysis, while in warfarin treated group the analysis was performed on seven surviving rats.
Analysis of proximal femur. Parameters of structure showed decreased bone volume and
increased trabecular separation in rats treated with warfarin with respect to dabigatran treated
and control rats (Figs 2 and 3). Reduced osteoblast activity was detected in warfarin treated
group (Fig 4). In addition, treatment with warfarin was associated with increased turnover,
characterized by increased resorption parameters and higher BFR/BS as a result of a similar
MAR with increased MS/BS. Consistently with these results, activation frequency (AcF) was
also higher in warfarin treated group than in dabigatran treated and control rats (Fig 3).
There were no substantial differences in microarchitecture among groups (Fig 2), with simi-
lar node number/tissue volume, marrow star volume, and fractal dimension and a little differ-
ence in node/termini ratio (N.Nd/TV, MSV, D and Nd/Tm D, Table 2).
Analysis of Vertebrae. The analysis of bone structure showed significant decreases in
bone volume and increases in trabecular separation in rats treated with warfarin compared to
dabigatran treated and control rats (Fig 5). In addition, trabecular number was lower in the
warfarin treated group than in the dabigatran group. Concerning the remodelling, we observed
significant difference in osteoblast activity (BFR/BS, Fig 6) and resorption parameters (ES/BS,
Fig 4) associated to higher Ac.F in warfarin-treated groups vs both others, suggesting that war-
farin may cause an increased turnover characterized by increased remodelling cycles, with
increased osteoclast activity with respect to other groups. No substantial differences in micro-
architecture, (N.Nd/TV, Nd/Tm, MSV, and D) were observed among groups, even though
there was a tendency towards altered microarchitecture parameters with warfarin treatment.
Thus, in the vertebrae, treatment with warfarin decreased bone volume with increased trabecu-
lar separation as a result of increased turnover and osteoclast activity, while treatment with
dabigatran maintained the parameters of structure and turnover similar to those in the control
group, showing, as a result, a bone sparing effect versus warfarin.
Fig 2. Dabigatran preserves femur volume and structure.Note the higher bone volume and trabecular thickness with lesser trabecular separation in rats
treated with dabigatran compared to rats treated with warfarin. Bone of a representative normal control rat is also shown. (magnification 100X).
doi:10.1371/journal.pone.0133847.g002
Dabigatran vs. Warfarin Effects on Bone
PLOSONE | DOI:10.1371/journal.pone.0133847 August 4, 2015 6 / 15
No differences in cortical thickness and porosity were found among groups, indirectly sug-
gesting that neither warfarin nor dabigatran affected parathyroid activity (data not shown).
Discussion
Warfarin, a vitamin K antagonist (VKA), reduces the risk of stroke in patients with atrial fibril-
lation but has some limitations, including an increased risk of bleeding and the need for close
monitoring. Such limitations led to the development of new oral anticoagulants. Dabigatran is
an oral direct thrombin inhibitor, whose administration to patients with atrial fibrillation was
associated with rates of stroke and systemic embolism similar as warfarin, but with lower rates
of major haemorrhage [17]. Warfarin as a VKA interferes with vitamin K actions, including
Fig 3. Significant histomorphometric results of structural and dynamic parameters in femur rats. In warfarin treated rats we observed lower bone
volume and trabecular thickness with increased trabecular separation compared to dabigatran treated and control rats. In addition, treatment with warfarin
was associated with a significant increase of turnover parameters (i.e. BFR/BS) and, in particular, activation frequency was higher in warfarin treated rats
versus dabigatran treated or control rats. Microarchitecture, cortical thickness and porosity were similar among groups. Only rats treated with warfarin
showed an alteration of bone volume and structure, suggesting increased bone fragility compared to dabigatran and control rats pattern. For the meaning of
abbreviations see Table 2. *p<0.05, **p< 0.01, ***p<0.001 vs control; # p<0.05, ##p< 0.01, ### p<0.001 vs dabigatran.
doi:10.1371/journal.pone.0133847.g003
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the carboxylation of vitamin K dependent proteins MGP and BGP causing critical adverse side
effects on bone and vascular health [18–20]. Dabigatran and other new oral anticoagulants do
not affect vitamin K metabolism. Thus, besides reducing major haemorrhage, they might also
attenuate serious adverse side effects induced by vitamin K deficiency, as vascular calcifications
and bone fractures.
This experimental study in rats shows that treatment with warfarin is associated with
significant bone abnormalities, differently from dabigatran and placebo treatment, but is not
associated with vascular calcification. The unexpected findings of absent calcification are in
accordance with a recent study by McCabe et al. demonstrating warfarin-induced vascular cal-
cification in CKD rats but not in animals with normal renal function [21] maybe because doses
of warfarin were lower than those previously employed to study the calcifying effects of antic-
oagulation treatment. Warfarin at high doses causes rapid calcification of rat arteries, with
Fig 4. Significant histomorphometric results of cellular parameters in femur (upper panel) and vertebra (lower panel) analysis of rats. The main
alteration of cellular parameters in warfarin treated rats was the increased osteoclast activity (ES/BS), although in femur a decreased osteoblast activity (OS/
BS) was also detected. ES/BS: Erosion Surface / Bone Surface; OS/BS: Osteoid Surface / Bone Surface. *p< 0.01 vs control; #p<0.001 vs dabigatran; ##p<
0.005 vs dabigatran.
doi:10.1371/journal.pone.0133847.g004
Dabigatran vs. Warfarin Effects on Bone
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Table 2. Histomorphometric parameters in femur and vertebra (S2 Dataset and S3 Dataset).
Femur Control (10) Warfarin (7) Dabigatran (10)
Trabecular Number (N) 4.74±1.36 3.83±1.13 4.43±1.46
Osteoid Thickness (O.Th., μm) 8,39±2,23 9.39±1,47 8,73±1,83
Osteoblast Surface/Bone Surface (Ob.S/BS, %) 0,74±0,31 0,87±0,28 0,76±0,34
Number of Osteoclast/Tissue Area (N.Oc/TA, /mm2) 2.08±1.36 1.08±0.21 1.72±0.60
Mineral Apposition Rate (μm/day) 0.40±0.13 0.39±0.10 0.39±0.14
Single Labelled Surface/Bone Surface sLS/BS (%) 2,45±1,09 4,12±1,13* 2,72±1,07
Double Labelled Surface/Bone Surface dLS/BS (%) 1,85±1,07 3,52±1,15* 2,11±1,12
MS/BS (%) 3,18±1,47 5,58±1,69* 3,48±1,60
Node Number/Tissue Volume (Nd.N/TV, %) 10.75±6.30 5.79±2.00 8.40±6.04
Marrow Star Volume (MSV, /mm3) 0.06±0.07 0.07±0.09 0.02±0.03
Fractal Dimension (D, #) 1.49±0.10 1.54±0.16 1.58±0.09
Vertebra
Osteoid Thickness (O.Th, μm) 8.55±2.21 10.98±1.08 10.85±2.56
Osteoblast Surface/Bone Surface (Ob.S/BS, %) 0.73±0.48 0.77±0.29 0.79±0.29
Number of Osteoclast /Tissue Area (N.Oc/TA, /mm2) 1.03±0.48 1.55±0.19 1.21±0.52
Mineral Apposition Rate (μm/day) 0.76±0.09 0.81±0.07 0.85±0.17
Single Labelled Surface/Bone Surface sLS/BS (%) 1,24±0,23 2,44±0,41** 1,27±0,50
Double Labelled Surface/Bone Surface dLS/BS (%) 0,64±0,33 1,84±0,44** 0,67±0,61
MS/BS (%) 1,25±0,34 3,01±0,61** 1,30±0,76
Node Number/Tissue Volume (Nd.N./TV %) 14.96±12.44 9.70±5.11 19.51±13.86
Node/Termini ratio (%) 0.52±0.15 0.59±0.27 0.78±0.34
Marrow Star Volume (MSV/mm3) 0.01±0.01 0.05±0.08 0.01±0.03
Fractal Dimension (D, #) 1.56±0.07 1.60±0.07 1.56±0.06
*p< 0.05 vs control and dabigatran groups;
** p<0.001 vs control and dabigatran groups.
doi:10.1371/journal.pone.0133847.t002
Fig 5. Dabigatran preserves vertebral volume and structure. According to what observed in the femur, analysis of vertebrae showed increased bone
volume, trabecular thickness and number, with lesser trabecular separation in rats treated with dabigatran with respect to warfarin treated study animals.
Bone of a representative normal control rat is also shown. No significant differences in microarchitecture were observed between study groups. Warfarin
treated rats showed thinner trabeculae with increased separation in the marrow space, highlighting a potentially increased fragility, despite similar
microarchitecture. (Magnification 100X).
doi:10.1371/journal.pone.0133847.g005
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aortic calcification seen after only 2 weeks of warfarin treatment [3]. In DBA/2 mice [22] and
in apolipoprotein E–deficient non-CKD mice [23], a recognized model of atherosclerosis, vas-
cular calcifications developed in less than 4 weeks with the administration of supra-therapeutic
doses of warfarin (3.0 mg/g of diet) even when the diet was supplemented with vitamin K1
(1.5 mg/g of diet). Such generation of vascular calcifications in response to warfarin adminis-
tration in mice is restricted to a genetic background, because the same protocol applied on
C57BL/6 mice did not result in comparable generation of vascular calcifications [22]. In both
studies [22,23], vitamin K1 was co-administered to avoid internal bleeding due to the high war-
farin dosage, because vitamin K1 antagonizes warfarin preferentially in liver but not in extra-
hepatic tissues [24]. Our approach was different, as we reproduced the usual clinical setting,
Fig 6. Significant histomorphometric results of structural and dynamic parameters in vertebrae of rats. Similar to the findings in femur, in warfarin
treated rats we observed lower bone volume and trabecular thickness with increased trabecular separation compared to dabigatran treated and control rats. In
addition, treatment with warfarin was associated with a significant increase of turnover parameters, i.e. BFR/BS and activation frequency. Microarchitecture,
cortical thickness and porosity were similar among groups. Only rats treated with warfarin showed an alteration of bone volume and structure, suggesting
increased bone fragility compared to dabigatran and control rats pattern. *p<0.05,** p< 0.01, ***p<0.001 vs control; #p<0.05, ## p< 0.01, ###p<0.001 vs
dabigatran.
doi:10.1371/journal.pone.0133847.g006
Dabigatran vs. Warfarin Effects on Bone
PLOSONE | DOI:10.1371/journal.pone.0133847 August 4, 2015 10 / 15
which is adapting warfarin dosage to keep the prothrombin INR in the 2 to 3 range. Further-
more, while high warfarin doses may block peripheral vitamin K activity, thereby inhibiting
the γ-carboxylation of vascular MGP and of bone osteocalcin, the endogenous conversion of
vitamin K1 to menaquinone-4 may contribute to the direct, osteocalcin-independent protective
effects on bone [25,26].
Although a more physiological approach was used in our study, standard animal diets
contain some vitamin K3 (menadione), which may have contributed to maintain synthesis of
carboxylated MGP. Vitamin K1 (phylloquinone) and vitamin K2 (menaquinones) are two nat-
urally occurring forms of vitamin K, while vitamin K3 (menadione) is an intermediate endoge-
nous metabolite of vitamin K, that also exists as a synthetic compound.
Vitamin K1 is the main (>90%) dietary source of vitamin K, but its tissue concentrations
are remarkably low compared with those of vitamin K2, the major form (>90%) of vitamin K
in tissues. Vitamin K1 appears to be converted into vitamin K2 in extra-hepatic tissues. In this
process, vitamin K3 is a catabolic product of vitamin K1 and a major source of tissue vitamin
K2 [27–30]. Even in humans, vitamin K1 can be endogenously converted to vitamin K2, either
directly or through vitamin K3. Nakagawa et al. identified the human enzyme responsible for
menaquinone-4 biosynthesis, UbiA prenyltransferase containing 1 (UBIAD1), a human homo-
logue of Escherichia coli prenyltransferase menA [31]. In mice, this enzyme was also localized
in endoplasmic reticulum and ubiquitously expressed in several tissues. Interestingly, experi-
mental menaquinone-4 biosynthesis by UBIAD1 was not affected by warfarin [31]. The
absence of calcifications in our experimental setting raises two important considerations for
therapy. First, that previous models of warfarin-induced vascular calcifications may not accu-
rately reflect the clinical setting, where lower doses of warfarin are used and a longer period of
vitamin K antagonism and abnormal bone metabolism may be necessary to detect an increased
arterial calcium deposition. Second, bone metabolism appears to be more sensitive than the
vasculature to the vitamin K inhibitory activity of warfarin.
Previous studies have established that vitamin K deficiency significantly affects bone health
[26, 32–36]. While there is some controversy as to whether warfarin decreases bone mineral
density [33], there is agreement on warfarin-induced risk of rib and vertebral fractures in
elderly patients [34–36], possibly by increasing skeletal fragility through the onset of vitamin K
deficiency. Thus, the increased risk of fractures in warfarin-treated patients might depend on
the impairment of bone quality rather than quantity [26, 37], and on the duration of treatment,
because there was no increased risk of osteoporotic fractures in patients prescribed warfarin for
less than a year [36]. Interestingly, different from vertebral fractures, long-term therapy with
warfarin did not increase the risk of hip fractures in the elderly [38, 39]. In an experimental set-
ting, Sugiyama et al. [26] partially explained this contradictory finding by considering the fun-
damental role of physical exercise and mechanical loading, suggesting that long-term warfarin
therapy weakens rib and vertebrae by impairing cortical bone quality. In addition, higher
mechanical stimuli in the hip prevent loss of bone strength through a compensatory adaptation
of cortical bone structure. However, in view of the direct impact of vitamin K on skeletal integ-
rity, a direct role of abnormal vitamin K metabolism cannot be ruled out.
Our detailed analysis of the negative effects of warfarin treatment compared to dabigatran
on bone structure and quality expands the current understanding of changes in bone histomor-
phometry during warfarin treatment. Amizuka [40] reported an inhibiting effect of warfarin
on mineralization and lower osteocalcin content in bone, with defective mineralization of the
osteoid. Haffa et al. evaluated markers of bone turnover, density, and strength in rats with war-
farin induced vitamin K insufficiency and reduced deposits of osteocalcin in bone, without hin-
dering the attainment of peak bone mass [41].
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The role of osteocalcin in bone remodeling and quality is still debated. In an experimental
study on the function of osteocalcin in bone, Lian et al. demonstrated that osteocalcin-deficient
bone particles obtained from warfarin treated rats were resistant to resorption when implanted
subcutaneously in normal rats [42], suggesting that osteocalcin is an essential component for
bone matrix to elicit progenitor-cell recruitment and the differentiation necessary for bone
turnover. However, Serre et al. could not reproduce their findings [43], and Karsenty´s group
reported an increased rather than reduced bone mass in the osteocalcin null mice [44].
In an experimental setting in monkeys on long-term warfarin anticoagulation, Binkley et al
did not find modifications of serum markers of bone turnover or BMDmeasured by DEXA
[45]. Again, these finding point to a qualitative, rather than quantitative bone damage of vita-
min K inhibition. Accordingly, Cheung et al. in a randomized controlled trial of vitamin K1
supplementation (5 mg/day) in postmenopausal women found no differences in BMD values
between the placebo and vitamin K groups, but fewer women in the vitamin K group had clini-
cal fractures [46].
A limitation of this study is the lack of bone biochemical markers. However, histological
analysis is a more powerful tool in detecting subclinical effects on bone of the tested drugs.
Results from our bone histomorphometry studies indicate that warfarin augments bone
turnover through an increase of osteoclastic activity (as indicated by the finding of deeper lacu-
nae) rather than by an increase in the number of osteoclasts. Bone microarchitecture was not
affected in our experiments. However, after a longer exposure to warfarin, which is associated
with increased osteoclastic activity, significant decreases in bone volume and increases in tra-
becular separation might determine alterations in bone quality and a higher propensity to
fractures.
On the other hand, the lack of an increased osteoclast activity along with the preservation of
structural parameters in the dabigatran treated group support a different impact of the two
treatments on bone, with dabigatran being safer in this context.
Conclusions
Treatment with warfarin in rats was associated with decreased bone volume, increased trabecu-
lar separation and higher turnover compared to that observed in dabigatran-treated or control
rats. These findings suggest that dabigatran has a better bone safety profile than warfarin. Since
warfarin treatment affects bone by reducing trabecular size and structure, increasing turnover
and reducing mineralization, these differences could translate into a lower incidence of frac-
tures in dabigatran treated patients.
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